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Objective. This study was to evaluate the efficacy and safety of a Chinese herbal medicine formula (RCM-104) for the management
of simple obesity. Method. Obese subjects aged between 18 and 60 years were selected for 12-week, double-blind, randomized,
placebo-controlled trial. Subjects were randomly assigned to take 4 capsules of either the RCM-104 formula (n = 59) or placebo
(n = 58), 3 times daily for 12 weeks. Measures of BW, BMI and WC, HC, WHR and BF composition were assessed at baseline
and once every four weeks during the 12 week treatment period. Results. Of the 117 subjects randomised, 92 were included in the
ITT analysis. The weight, BMI and BF in RCM-104 group were reduced by 1.5 kg, 0.6 kg/m2 and 0.9% and those in the placebo
group were increased by 0.5 kg, 0.2 kg/m2 and 0.1% respectively. There were significant differences in BW and BMI (P < 0.05)
between the two groups. Eleven items of the WLQOQ were significantly improved in the RCM-104 group while only 2 items were
significantly improved in the placebo group. Adverse events were minor in both groups. Conclusion. RCM-104 treatment appears
to be well tolerated and beneficial in reducing BW and BMI in obese subjects.
1. Introduction
Obesity is a common metabolic disorder in developed and
developing countries [1] and is characterized by weight
gain, fatigue, and lassitude. Obesity is associated with
serious health conditions such as hypertension (32.1%),
osteoarthritis (38.9%), joint pain (27.4%), chronic insomnia
(23.4%), allergy (37.3%), and depression (23.4%) [2]. The
increasing prevalence of obesity is a major public health
concern since obesity is often associated with cerebrovascular
and cardiovascular diseases such as hypertension and arte-
riosclerosis, as well as diabetes mellitus and the acceleration
of the aging process [3]. The prevalence of obesity has
risen to alarming levels worldwide with the World Health
Organization (WHO) estimating that there will be 2.3
billion overweight and 700 million obese adults by 2015. In
Australia, 25% of the population is obese [4], whereas in the
US it is estimated that 30.4% of adults are obese [5, 6].
Current management of obesity by pharmacotherapy
includes noncentrally acting antiobesity agents such as
Orlistat (Xenical), which inhibits the action of the intestinal
lipase enzymes and hence blocks the absorption of fat in
the intestines. The most common adverse events of Orlistat
include oily faecal spotting, abdominal pain, and flatus
with discharge, faecal urgency, fatty/oily stool, increased
defecation, and faecal incontinence [7].
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Another pharmacotherapy is the centrally acting an-
tiobesity agent, namely, Sibutramine (Reductil), which
produces unwanted side effects such as trouble sleeping,
constipation, and dry mouth as well as increased heartbeat,
increased blood pressure, awareness of the heartbeat (pal-
pitations), headache, anxiety, or dizziness [8–10]. Conse-
quently, the Food and Drug Administration (FDA) of the
USA withdrew Sibutramine in October 2010.
Surgical procedures such as gastric bypass operations
are generally reserved for people with morbid obesity (BMI
> 40) who instituted but failed an adequate exercise and
diet program (with or without adjunctive drug therapy)
or patients presenting with comorbid conditions such as
hypertension, impaired glucose tolerance, diabetes mellitus,
hyperlipidaemia, and obstructive sleep apnoea [11].
Chinese herbal medicine has been used for weight
management both in China and in western countries [12].
However, there is a lack of rigorously conducted random-
ized, controlled clinical trials published on Chinese herbal
medicines for weight management in the international peer-
reviewed scientific literature.
In 2004, Hioki et al. demonstrated the effectiveness and
safety of a traditional Chinese formula (Bofutsusho-san)
in obese Japanese women with impaired glucose tolerance.
Findings from this study revealed significant improvement
in both treatment and placebo groups compared to baseline.
However, waist and hip circumference measurements of
subjects in the Bofutsusho-san treatment group were also
significantly improved compared to that of the control group
[13].
A number of animal studies support the use of Chinese
herbal medicine formulas for treating obesity and have
shown other beneficial effects. For example, the Bofutsusho-
san formula has been shown to prevent intimal thicken-
ing and vascular smooth muscle cell proliferation in rats
[14]. Furthermore, an in vivo study demonstrated that a
Chinese herbal formula significantly reduced the weight
of overweight rats and suppressed their appetites [15]. A
herbal treatment, known as 9D-ASR also leads to a decrease
in the weight of overweight rats [16, 17]. Another herbal
formula (PM-F2-OB) also demonstrated anti-obesity effects
in overweight rats [18]. To evaluate the potential mechanism
of actions of many Chinese herbs that are traditionally used
for weight management, Tian et al. carried out investigations
of 31 herbs on rats and found that 17 of them inhibited
the enzyme, fatty acid synthase [19]. It was also interesting
to note that some agents such as conjugated linoleic acid,
catechins, and synephrine hydroxycitric acid often used
for weight reduction were also found in Chinese herbal
medicines [20, 21].
Until recently, widely used herbal supplements for weight
loss contained ephedra alkaloids and herbal forms of caf-
feine, which are constituents of Mahuang [20]. Many clinical
trials have been conducted to investigate the effectiveness
of these two constituents for treating obesity [22, 23].
However, certain adverse effects associated with ephedrine
and caffeine, such as central nervous system stimulation and
increases in blood pressure and serum glucose, have been
reported [20]. The use of ephedra can lead to life-threatening
adverse cardiac effects [24], which include myocardial infarc-
tion, stroke, and death outside of a hospital [25]. Conse-
quently, the sale of products containing ephedrine has been
prohibited in the USA [26, 27]. There have also been reported
cases of hepatotoxicity caused by Chinese dietary weight loss
formulas containing fenfluramine and nitroso-fenfluramine.
Kidney diseases or urothelial carcinoma related to the use of
Chinese herbs containing aristolochic acids have also been
reported [28]. RCM-104, the Chinese herbal formula used in
the present study, contained none of these substances.
RCM-104 is an RMIT Chinese herbal medicine formula
with three herbal ingredients that are commonly used in
daily practice. These 3 herbs were carefully selected based
on both Chinese medicine theory and existing published
literature of basic research. A previous study on green
tea extract had shown a 4.6% decrease in body weight
and 4.5% decrease in waist circumference after 12 weeks,
possibly via inhibition of intestinal lipases and stimulation
of thermogenesis [29].
The aim of this study was to evaluate the efficacy
and safety of RCM-104 through a rigorous double-blinded,
randomized, placebo-controlled clinical trial.
2. Methods
2.1. Study Design. The trial was approved by the RMIT
University Human Research Ethics Committee, and a Clin-
ical Trial Notification (CTN) application was filed with
the Therapeutic Goods Administration (TGA-2007/313),
Department for Health and Ageing, Australian Federal Gov-
ernment, Canberra, Australia. The trial has been registered
with Australian and New Zealand Clinical Trial Registry
(ACTRN12607000255482).
Subjects and personnel who were involved in the clinical
trial were blinded to the participant’s group allocation. A
pharmacist, responsible for prepacking and dispensing the
RCM-104 and matched placebo capsules into identical pack-
ages, was the only person with access to the randomization
allocation codes.
Subjects were given written information and a verbal
explanation concerning the study prior to obtaining con-
sent for their participation. After the two-week baseline
assessment, the subjects were randomly assigned into either
the RCM-104 treatment or placebo groups using treatment
allocation codes generated by a statistician and designed to
ensure balance of gender, age, and severity of obesity between
groups (Figure 1).
Subjects were required to take either the RCM-104 or
placebo capsules for 12 weeks with measures of BW, BMI,
and body fat taken once every 4 weeks as well as at 12 weeks
after intervention.
2.2. Subjects. Subjects’ ages ranged from 18 to 60 years with
a BMI ≥ 30 kg/m2. The exclusion criteria were (1) losing
more than 5 kg in the past 3 months; (2) endocrine disor-
ders other than type 2 diabetes mellitus; (3) uncontrolled
hypertension; (4) autoimmune or cardiovascular diseases or
carrying a pace-maker; (5) lactating or pregnant women;
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134 initial interviewed and assessed
117 randomised
59 RCM-104 group
55 received placebo
58 placebo group
42 remaining after first treatment period50 remaining after first treatment period
41 completed trial46 completed trial
57 received RCM-104 
17 excluded (not meeting criteria)
2 change of mind 3 change of mind
1 dropped out 
(personal choice)
50 included in the data analysis (ITT) 42 included in the data analysis (ITT)
7 dropped out (personal
choice, did not return for
assessment)
13 dropped out (personal
choice, did not return for
assessment)
4 dropped out (1
tired due to caffeine,
3 personal choice)
Figure 1: Clinical trial profile.
(6) those using drugs affecting the central nervous system
or lipid lowering drugs; (7) obesity known to be caused by
pharmacotherapy; (8) therapy for weight control in the last
6 months; (9) renal or hepatic disease; (10) unable to read
or understand English. The subjects were not allowed to
receive other obesity management and were asked to keep to
their existing diet and life style during the study period. All
subjects were free to withdraw at any time during the course
of the study.
The study was advertised in the local newspapers and
websites. Flyers advertising the study were displayed in
local medical centers and university campuses. After a brief
telephone screening interview, subjects were invited to a face-
to-face interview to ensure they understood the aims of the
trial and satisfied the inclusion and exclusion criteria.
2.3. Treatment. All subjects were instructed to take 4
capsules per time, three times per day. The treatment
group received RCM-104 capsules containing 500mg gran-
ule extract from dried herbals according to the pre-set
standard procedures with certificate of analysis. The stan-
dardmarkers were Chrysophanol (0.0317mg/g), Epicatechin
(EC—10.89mg/g), Caffeine (31.24mg/g); Epigallocatechin
gallate (EGCG—52.34mg/g); Epicatechin gallate (ECG—
13.63mg/g) and Rutin (62.09mg/g). The ingredients include
Camellia sinensis (Lu Cha Ye: 40%), Cassia obtusifolia (Jue
Ming Zi: 40%), Sophora Japonica (Huai Hua: 20%). These
ingredients are listed in Australian Register of Therapeutic
Goods (ARTG) as approved substances for human con-
sumption by the Therapeutic Good Administration (TGA).
The placebo group received herbal starch capsules that
contained no active substances, with an identical appearance
to the RCM-104 capsules. Both granules of RCM-104 and
placebo were in standard capsules produced by Sun Ten
Pharmaceuticals Co Ltd Taiwan that holds a TGA approved
Good Manufacturing Practice (GMP) certificate. The trial
medication compliance was monitored by counting left-
over capsules to determine the number of capsules taken by
subjects and checking on the completeness of the data on
forms returned to the trial team.
2.4. Measurements. All anthropometric measurements were
carried out using standardized methods and performed at
the beginning of each 4 weekly visit. Height was measured
with a wall-mounted stationmaster without wearing shoes
to the nearest 0.1 cm; weight was measured while wearing
light clothes without shoes on a calibrated balance beam
scale to the nearest 0.1 kg. BMI was calculated according
to the formula: BMI = body weight (BW)/squared height
(kg/m2). Waist circumference (WC) was measured mid-way
between the lateral lower rib margin and the iliac crest,
and hip circumference (HC) was measured at the levels
of the prominence of greater trochanters. Body fat (BF)
composition was determined using a standard Bioimpedance
Analyzer (BIA, Model HBF-522; Omron, Kyoto, Japan)
which calculated lean mass and fat mass using an algorithm
based on electrical resistance, weight, age, height, and gender.
The resting metabolic rate was determined by Fitmate
(Biomedex Pty. Ltd. 1/1 Pioneer Drive, Bellambi, NSW,
Australia). Subjects were instructed not to exercise or
consume stimulants such as alcohol, tea, or coffee at least 2
hours prior to the test. Blood pressure and heart rate were
measured three times in a resting seated position with the
rest period of 1 minute between the measurements using
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ITO blood pressure monitor, and the average of all three
measurements was recorded.
Blood collections for serological data were conducted
only at the first and the last visit (week 12). The serological
data included cholesterol, low density lipoprotein cholesterol
(LDL), high-density lipoprotein (HDL) cholesterol, triglyc-
erides, fasting insulin and glucose for calculation of insulin
sensitivity (HOMA-IR), and renal and liver functions tests.
Self-assessment questionnaires were used to monitor
quality of life using validated Weight-Related Symptom
Measure (WRSM) and the Obesity & Weight-Loss Quality
of Life measure (OWLQOL) questionnaires (University of
Washington, 2004) prior to each visit.
2.5. Food Intake Records. Subjects were asked to maintain
their normal diet and routine activities. They were instructed
to record their diet in the dietary record form. The forms
include day by day, meal by meal records of all food and
liquids consumed over 3 days at the beginning of the trial and
further random 3 days in each treatment period. The food
intake records were subsequently analysed using a standard
dietary software package (FoodWorks, Xyris, Brisbane, Aus-
tralia) incorporating the latest Australian database of food
composition (NUTTAB 2006, FSANZ, Canberra, Australia).
Nutrient intake was averaged over the initial 3-day period
to determine the daily intake of macro- and micronutrient,
fat subtypes, and total energy as the subject’s baseline diet.
Dietary data collected during study periods were compared
to baseline to determine any change in dietary intake (data
not provided).
2.6. Statistical Analysis. All data were analysed using the
Statistical Package for the Social Sciences (SPSS, version 18
for Windows). Intention to treat (ITT) analysis included all
randomized patients with baseline data with at least one
outcome after the interventions were determined using the
last-value-carried-forward method. Outcomes were evalu-
ated by comparing baseline data with data after 4 weeks of
intervention for the variables BW, BMI, WC, HC, Hip to
waist ratio (HWR), and BF.
The data from nonrepeated measures including blood
tests were analyzed using t-tests. Ordinal data variables
involving baseline and end of study within each treatment
group were analyzed using the Wilcoxon signed-rank test.
Gender balance in the two groups was assessed using the
Chi-square test. ANCOVA was used to assess whether the
treatment and placebo groups were significantly different on
variables assessed at the end of the study using baseline as
covariate. All statistical tests were assessed at α = 0.05 with
adjustments to α where necessary to accommodate testing
involving multiple outcomes.
3. Results
3.1. Baseline Subject Characteristics. Of 133 obese subjects
screened, 117 fulfilled the inclusion criteria and were ran-
domized into placebo (n = 59) and treatment groups (n =
58, Table 1).
Table 1: Demographic and baseline health characteristics of all
randomized subjects by group.
RCM-104
(n = 59,
Mean ± SD)
Control
(n = 58,
Mean ± SD)
P-value
Gender
Male 10 10 0.97
Female 49 48
Age (years) 39.3± 13.2 40.4± 10.2 0.61
Weight (kg) 99.5± 15.1 98.2± 17.3 0.67
Male 105.5± 15.1 108.3± 21.1 0.41
Female 98± 14.7 96.8± 16.1 0.67
BMI (kg/m2) 35.3± 4.8 36.0± 5.5 0.47
Heart rate (beats/min) 72.6± 9.2 73± 11.4 0.84
Systolic blood pressure
(mmHg)
122.8± 15.5 126.2± 19.8 0.30
Diastolic blood pressure
(mmHg)
80.8± 10.8 82.9± 13.7 0.16
HbA1c (%) 5.3± 0.3 5.6± 0.8 0.008
Triglyceride (mmol/L) 1.5± 0.8 1.6± 0.8 0.50
Total Cholesterol (mmol/L) 5.6± 1.5 5.5± 1.5 0.71
LDL Cholesterol (mmol/L) 3.6± 0.8 3.6± 1.5 1.00
HDL Cholesterol (mmol/L) 1.5± 0.08 1.4± 0.23 0.002
Insulin (mIU/L) 10.7± 9.2 15.1± 3.6 0.001
Glucose (mmol/L) 4.8± 0.5 5.2± 1.5 0.058
Homa-index (%) 2.3± 2.2 3.9± 1.0 <0.001
Thirteen (13) subjects of the treatment group and 17
subjects of the placebo group prematurely withdrew before
the commencement of the treatment phase or did not
return for the assessment after the first treatment period
due to personal and other reasons. Ninety-two subjects were
included in an ITT analysis. No subjects were removed
or withdrew from the study due to serious adverse events
(Figure 1).
3.2. Treatment Effects
3.2.1. Body Weight, BMI, and Body Fat Composition. At
baseline, the placebo group had a mean weight (98.2 ±
17.3 kg) and mean BMI (36.0±5.5 kg/m2) similar to those in
the treatment group (99.5±15.1 kg), (35.3±4.8), respectively.
ANCOVA was used for assessing treatment outcomes in
weight and BMI between the two groups after 12 weeks
of treatment using the baseline as a covariate. When both
groups were compared after 12 weeks of treatment with
the baseline as covariate, there was a significant difference
between the two groups on weight (P = 0.006, Figure 2) and
BMI (P = 0.027, Figure 3). Note that we used Hochberg’s
step-up procedure to control Type I error to assess statistical
significance. In doing so, we included BW, BMI, and BF
composition as the three core variables that were used to
assess the efficacy of the treatment. Within the treatment
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Figure 2: Average weights (Kg) after 12-week treatment. The
plotted line graphs indicate the means ± SD of change of weight
at each assessment visit, RCM-104 group () and placebo control
group (♦). (∗) indicates value that is significantly different from
that of placebo group using ANCOVA and ITT, (P = 0.006).
group, the reduction in weight and BMI were statistically
significant.
The analysis showed that after 12 weeks of treatment,
there was no significant reduction in the BF composition
between the RCM-104 group and the placebo group (P =
0.151, Figure 4).
3.2.2. Quality of Life. At baseline, there were no statistically
significant differences in any of the 20 quality of life measures
(Weight-Related Symptoms and How Much They Bother
You) between the two groups. The RCM-104 group showed
significant improvement compared to baseline on only two
items of the quality of life measure, which assessed shortness
of breath and physical stamina (P = 0.001), while the placebo
group showed no significant improvement on any of the
items after controlling for Type I error due tomultiple testing
via the Holm’s step-down procedure (Table 2). (The smallest
P-value was compared against α/m, the next smallest against
α/(m − 1), etc., where α = 0.05 and m = 20 variables. Note
that we have only included 5 of the 20 variables in Table 2 on
the basis of having the smallest P-values. All other variables
had associated P-values, which were large enough not to
have reached significance.) When the RCM-104 group was
compared to the placebo group after 12 weeks of treatment,
an ANCOVA analysis with baseline as the covariate, and
using the Holm step-down procedure, as described above,
for controlling Type I error, the only quality of life measure
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Figure 3: Average body weight index (Kg/m2) after 12-week
treatment. The plotted line graphs indicate the means ± SD of
change of BMI at each assessment visit, RCM-104 group () and
placebo control group (♦). (∗) indicates the values significantly
different than that of placebo group using ANCOVA and ITT, (P =
0.027).
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Figure 4: Change in body fat composition (%) after 12-week
treatment. The plotted line graphs indicate the means ± SD of
change of body fat composition at each assessment visit, RCM-104
group () and placebo control group (♦). (#) indicates value not
significantly different using ANCOVA and ITT, (P > 0.05).
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Table 2: Weight-related symptoms and how much they bother you.
Symptoms Study period
RCM-104 (n = 48)#
value ± SD
Placebo (n = 42)
value ± SD P value
∗∗
Shortness of breath
Baseline 1.2± 1.27 1.1± 1.23
Final 0.6± 0.92 1.2± 1.21
P value∗ 0.001 0.760 0.002
Sensitivity to cold
Baseline 1.0± 1.57 0.8± 1.12
Final 0.5± 0.92 0.9± 1.23
P value∗ 0.008 0.628 0.011
Leakage of urine
Baseline 0.4± 1.09 0.4± 0.73
Final 0.4± 0.91 0.8± 0.93
P value∗ 0.521 0.005 0.005
Increased sweating
Baseline 0.9± 1.56 0.7± 1.20
Final 0.5± 1.11 0.8± 1.15
P value∗ 0.030 0.547 0.057
Decreased physical stamina
Baseline 1.6± 1.91 1.2± 1.54
Final 0.7± 1.23 1.1± 1.53
P value∗ 0.001 0.660 0.049
Joint pain
Baseline 1.5± 1.62 1.8± 1.83
Final 0.8± 1.18 1.6± 1.56
P value∗ 0.003 0.748 0.007
Weight-Related Symptom Measure (WRSM) is 7-point scaled: 0 = not at all; 1 = hardly; 2 = somewhat; 3 = moderately; 4 = a good deal; 5 = a great deal; 6 = a
very great deal.
∗Comparison within the group between baseline and final visits using Wilcoxon-signed rank test.
∗∗Comparison between groups at the end of trial.
For the above, the P values were assessed using Holm’s step-down procedure, with α = 0.05/20 = 0.0025 for assessing the smallest P value, α = 0.05/19 =
0.0026 for the next smallest P value, and so forth. Significant P values are indicated in bold [30]. Note: only results for symptoms showing small P values are
displayed.
#Sample size for treatment group reduced from 50 to 48 as Quality of Life data were unavailable for two participants.
that showed significant difference in symptoms between the
two groups was shortness of breath (P = 0.002) with the
RCM-104 group showing significant reduction in symptoms
(P = 0.001, Table 2).
Similarly, after 12 weeks, eleven items of Weight-Loss
Quality of Life (your feelings about your weight—Table 3)
were significantly improved in the treatment group, while
only 2 items were significantly improved in the placebo
group. When the RCM-104 group was compared to the
placebo group after 12 weeks of treatment, an ANCOVA
analysis with baseline as the covariate, and using the Holm’s
step-down procedure for controlling Type I error, there were
no statistically significant differences between the two groups
on all of the 17 items except one (“I get discouraged when
I try to lose weight”) on the Weight-Loss Quality of life
Scale. (Here we used α = 0.05/17 = 0.0029 for assessing the
smallest P-value (Table 3)).
3.2.3. Resting Metabolic Rate (RMR) and Food Intake. Both
within group and between the groups analyses did not reveal
significant changes in RMR (Table 4) for both groups.
There were some changes in the food intake by the
subjects during the trial. However, the changes were not
significant (data will be presented in a future journal article).
3.2.4. Laboratory Data. There were no significant differences
between the two groups with respect to renal and liver
function tests before and after the treatment period. Simi-
larly, there were no statistically significant differences in the
serological data between the 2 groups.
3.2.5. Medication Compliance. Overall, the compliance of
medication was 88% with 88.6% in the placebo and 87% in
the treatment group.
3.2.6. Self-Reported Undesired Symptoms. Within the RCM-
104 group, there were reports of nausea (4 cases) and
headache (9 cases) while there were 2 reports of decrease
in appetite in the placebo group. Both of these symptoms
occurred during the first treatment period and none of these
were serious. No subject withdrew from the study due to
adverse events.
4. Discussion
This study was designed to evaluate the effect of a Chinese
herbal medicine formula RCM-104 in the treatment of
simple obesity. There was a high level of willingness to
participate in this study as all 117 subjects who satisfied
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Table 3: Obesity and weight-loss quality of life-your feelings about your weight.
Symptoms Study period
RCM-104 (n = 48)#
value ± SD
Placebo (n = 42)
value ± SD P value
∗∗
Because of my weight, I try to wear clothes
that hide my shape
Baseline 4.0± 1.57 3.9± 1.74
Final 3.0± 1.94 3, 5± 1.67
P value∗ <0.001 0.033 0.021
I feel frustrated that I have less energy
because of my weight
Baseline 3.5± 1.91 3.2± 1, 77
Final 2.54± 1.97 2.8± 1.61
P value∗ <0.001 0.058 0.025
I feel guilty when I eat because of my weight
Baseline 3.3± 1.80 3.0± 1.75
Final 2.5± 01.94 2.7± 1.76
P value∗ <0.001 0.025 0.093
I am bothered about what other people say
about my weight
Baseline 2.8± 2.06 2.9± 1.75
Final 2.21± 1.99 2.5± 1.77
P value∗ 0.033 0.047 0.590
Because of my weight, I try to avoid having
my photograph taken
Baseline 3.1± 2.17 3.4± 2.07
Final 2.35± 2.09 2.95± 1.94
P value∗ 0.002 0.016 0.374
My weight prevents me from doing what I
want to do
Baseline 2.7± 2.06 2.9± 1.73
Final 2.2± 1.86 2.3± 1.65
P value∗ 0.045 0.001 0.608
I worry about the physical stress that my
weight puts on my body
Baseline 3.6± 1.86 3.9± 1.78
Final 2.8± 1.83 3.4± 1.71
P value∗ 0.003 0.028 0.329
I feel depressed because of my weight
Baseline 2.9± 1.92 2.8± 1.74
Final 2.3± 2.02 2.6± 1.78
P value∗ 0.001 0.148 0.106
I feel ugly because of my weight
Baseline 3.1± 2.05 3.1± 1.84
Final 2.4± 2.19 2.6± 1.97
P value∗ <0.001 0.002 0.072
I worry about the future because of my
weight
Baseline 3.6± 1.89 3.4± 1.68
Final 2.5± 1.82 3.2± 1.60
P value∗ <0.001 0.231 0.702
I envy people who are thin
Baseline 2.8± 2.12 2.6± 1.96
Final 2.2± 2.08 2.4± 2.08
P value∗ <0.001 0.382 0.267
I feel that people stare at me because of my
weight
Baseline 2.3± 1.99 1.8± 1.79
Final 1.8± 1.95 1.5± 1.66
P value∗ 0.014 0.254 0.332
I have difficulty accepting my body because
of my weight
Baseline 3.0± 2.13 2.9± 1.93
Final 2.3± 2.05 2.6± 1.90
P value∗ 0.006 0.170 0.179
I am afraid that I will gain back any weight
that I lose
Baseline 3.8± 1.91 3.7± 1.72
Final 2.9± 2.13 3.3± 1.97
P value∗ 0.002 0.019 0.149
I get discouraged when I try to lose weight
Baseline 3.7± 1.92 3.1± 2.03
Final 2.7± 2.18 3.1± 1.99
P value∗ <0.001 0.848 0.002
Obesity & Weight-Loss Quality of Life measure (OWLQOL) questionnaires are 7-point scaled: 0 = not at all; 1 = hardly; 2 = somewhat; 3 = moderately; 4 = a
good deal; 5 = a great deal; 6 = a very great deal.
∗Comparison within the group between baseline and final visits using Wilcoxon signed-rank test.
∗∗Comparison between groups at the end of trial.
For both the above, the P values were assessed using Holm’s step-down procedure, with α = 0.05/17 = 0.0029 for assessing the smallest P value, α = 0.05/16 =
0.0031 for the next smallest P value, and so forth. Significant P values are indicated in bold.
Note: only symptoms showing small P values are displayed.
#Sample size for treatment group reduced from 50 to 48 as Quality of Life data were unavailable for two participants.
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Table 4: Changes in anthropometric parameters of RCM-104 and placebo groups.
Study period
RCM-104 (n = 50)
value ± SD
Placebo (n = 42)
value ± SD P value
∗∗
Body weight (kg)
Baseline 99.5± 15.1 98.2± 17.3
Final 98.0± 15.4 98.7± 17.5
P value∗ 0.002 0.510 0.006
Body mass index (kg/m2)
Baseline 35.9± 4.9 35.9± 5.9
Final 35.3± 5.7 36.1± 5.9
P value∗ 0.008 0.676 0.027
Body fat (%)
Baseline 42.2± 9.2 42.9± 8.4
Final 41.3± 9.2 43.0± 7.8
P value∗ 0.104 0.935 0.151
Waist circumference (cm)
Baseline 108.5± 12.3 107.4± 11.04
Final 106.6± 12.5 106.3± 12.3
P value∗ 0.014 0.182 0.445
Hip circumference (cm)
Baseline 124.4± 12.3 124.7± 12.5
Final 122.9± 12.0 125.1± 12.8
P value∗ 0.034 0.544 0.042
Waist to Hip Ratio
Baseline 0.87± 0.08 0.87± 0.08
Final 0.87± 0.07 0.85± 0.081
P value∗ 0.382 0.067 0.356
Systolic Blood pressure (mmHg)
Baseline 122.8± 14.1 126.2± 16.8
Final 117.8± 14.0 118.3± 15.6
P value∗ 0.738 0.854 0.685
Diastolic blood pressure (mmHg)
Baseline 80.8± 9.9 82.9± 11.7
Final 81.1± 9.8 81.8± 10.4
P value∗ 0.853 0.855 0.934
Heart rate (beats/min)
Baseline 72.6± 8.5 73.1± 9.7
Final 74.6± 9.2 73.2± 9.1
P value∗ 0.084 0.897 0.281
RMR (Kcal/day)
Baseline 1353.8± 353 1333.3± 315
Final 1478.9± 330 1450.6± 276
P value∗ 0.085 0.019 0.827
∗
Comparison within the group between baseline and final visits.
∗∗Comparison between groups at the end of trial.
(ANCOVA, using baselines as covariate). Body Weight, Body Mass Index, and Body Fat were used as a single family of variables when assessing significance
using Hochberg’s Step-up procedure for adjusting significance levels as these variables were the focus of the study.
inclusion criteria gave informed consent to participate in the
trial.
The results of the present study showed statistically sig-
nificant differences in BW and BMI between the participants
of RCM-104 and placebo groups after 12 weeks of treatment
and significant improvements in quality of life of participants
in the RCM-104 group.
Because obese individuals often have other associated
health issues, guidelines for obesity management prefer
modest and safe weight loss and good weight maintenance
to target an ideal weight [31].
The RCM-104 is composed of 3 herbs: Camellia Sinensis
(Lu Cha Ye—Green tea), Semen Cassiae (Jue Ming Zi),
and Flos Sophorae (Huai Hua). While the mechanism of
actions of this formula is unknown, a study has shown
that green tea extract stimulated thermogenesis and fat
oxidation potentially may influence body weight and body
composition by increasing energy expenditure [32].
It has been suggested that synergistic interactions
between catechin-polyphenol and caffeine augment and
prolong sympathetic stimulation of thermogenesis and that
this may play an important role in the management of
obesity [32]. Thus the actions of green tea may contribute
to reducing body fat as previous experimental and clinical
studies have reported that green tea extract, which is
rich in catechins and caffeine, is an effective potentiator
of sympathetically mediated thermogenesis [33]. Further
actions of green tea include EGCG’s inhibition of the enzyme
catechol-O-methyltransferase, which prolongs the action of
catecholic compound on energy expenditure [33]. Studies
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also suggested that EGCG stimulates thermogenesis, with
caffeine enhancing this action. Other studies have found that
catechin polyphenols and caffeine increase 24-hour energy
expenditure and fat oxidation in humans, which contribute
to weight reduction [33]. This present study did find some
increase in RMR; however, the difference between the two
groups was not significant.
In Chinese medicine practice, Jue Ming Zi is known
to clear heat, moistens and lubricates the intestines, and
therefore acts as a mild laxative [34]. The anti-obesity effects
of this herb, however, may be attributed to the inhibition
of fatty acid synthase [19], which is shown in the reduction
of body fat composition. Traditionally, Huaihua is used to
cool blood and stop bleeding which is an anti-inflammatory
effect. The anti-obesity effect of Huaihua is attributed to its
diuretic and laxative actions [35].
In human studies, green tea has been found to signifi-
cantly increase energy expenditure, lower body weight, and
decrease waist circumference without changing heart rate
or blood pressure [33]. Obesity is associated with many
other health problems [2] and even small reductions in
weight can lead to significant improvements in quality of
life of obese individuals [36]. In this study, we found that
RCM-104 significantly improved many aspects of quality of
life consistent with Chinese medicine diagnosis theory. The
reduction of joint pain among the participants in this study
may be due the anti-inflammatory action of Huaihua and
Juemingzi [35]. The cholesterol levels have been unchanged,
which is not consistent with an animal study by [37] that
Huaihua lowered hepatic and blood cholesterol levels, but
may be due to a relatively small proportion of Huaihua in
RCM-104. Chronic obstructive pulmonary disease (COPD)
often coexists within the obese population [38]. In this
study, subjects in the treatment group showed significant
improvement of shortness of breath symptoms. This effect
maybe due to the antioxidant effects of green tea catechins
[39].
There has been general concern of the lack of safety
of specific Chinese herbal medicine. Kidney failure due
to herbal weight loss pills has been reported [40]. The
results of this study have shown only mild undesirable
adverse events such as headache and nausea that occurred
during the first treatment period. This is consistent with
reports from previous studies [41, 42]. A study by Pisters
et al. in 2001 showed that a single oral consumption of
800mg epigallocatechin gallate (EGCG) might cause mild
headache [43, 44]. A study by Hsu et al. 2008 did not
detect EGCG in the serum sample of subjects at the dosage
of 302mg of EGCG per day. In the present study, RCM-
104 contained 314.04mg of EGCG in the daily dosage. It
has been previously reported that green tea could cause
slight gastrointestinal disturbances such as nausea [45].
Although Juemingzi is included in the list of poisonous
plants of North Carolina, Russell et al. stated that the toxic
effects are only associated with the intake of large quantities
without specifying dosage [46]. However, an animal study
has shown no changed serum aspartate aminotransferase,
creatine phosphokinase, and lactic dehydrogenase activity at
the dosage of 1.19% of body weight per day [47]. Another
animal study did not see any sign of chronic ingestion when
consuming 0.15% Juemingzi of the diet, and Intermittent
mild diarrhea was observed in animals consuming high doses
(5%) of Juemingzi in their diet [48]. Juemingzi has been
safely used in Chinese medicine practice for hundreds of
years. In this study, we used 2.4 g of Juemingzi extract, which
is less than half of recommended dosage of 5 g extract per
day [35]. Huaihua has been used in many Asian countries as
daily tea. In daily practice, overuse of Huaihua can causemild
diarrhea in some cases [35]. The recommended safe dosage
for this herb is 5 g [34] of extract per day, but only 1.2 g per
day was used in this study. Based on the dosages used in this
study and the findings, RCM-104 appeared to be safe and
well tolerated by the subjects.
5. Conclusion
RCM-104 is well tolerated and appears to be effective in
reducing weight and improving quality of life in obese
individuals after 12 weeks. Long-term follow-up studies in
larger populations are required to determine if weight loss is
sustained.
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